- Global Pharma News & Resources

Director resignation - H.J. Mark Tompkins

The Company announces that Dr. B.R. Shetty has resigned as a director and Joint Non-Executive Chairman of the Company with immediate effect on 16 February 2020. 

H.J. Mark Tompkins will continue as the sole Non-Executive Chairman of the Company.  


Investors NMC Health plc  Simon Watkins, Group Company Secretary +44 (0) 203 205 7313 Asjad Yayha, Head of Investor Relations +971 (0) 56 219 0975 


FTI Consulting, London  Edward Bridges / Simon Conway / Victoria Foster Mitchell +44 (0)20 3727 1000   FTI Consulting, Gulf  Shane Dolan +971 (0)4 437 2100 

About NMC Health 

 NMC is one of the leading private healthcare operators in the Gulf Cooperation Council (“GCC”) with an international network of multi-specialty inpatient and outpatient clinics and hospitals, specialized maternity and fertility clinics, and long-term care homes hospitals across nineteen countries. NMC also ranks as one of the top two in-vitro fertilisation operators globally. The NMC Health group is recognised as a leading provider of long-term medical care in the UAE through its subsidiary ProVita. Pursing a selective international expansion programme since 2016, NMC has total capacity of 2,207 licensed beds across its network. Moreover, the recent formation of a joint venture with GOSI/Hassana Investment Company provides a solid platform for continued growth in the GCC region’s largest healthcare market. The NMC Health group treated over 7.5 million patients in 2018. The NMC Health group is also a leading UAE supplier of products and consumables coming from healthcare related products. NMC reported revenues of US$2.1 billion for the year ended 31 December 2018.    In April 2012, NMC was listed on the Premium Segment of the London Stock Exchange. NMC is a constituent of the FTSE 100 Index. 

Editor Details

  • Company:
  • Name:
Last Updated: 18-Feb-2020